씨엔에스파마슈티컬스(CNSP)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $5.08 (-0.78%), 시가총액 $0.01B, 52주 최저~최고 $0.74 ~ $10.57.
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.
씨엔에스파마슈티컬스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
씨엔에스파마슈티컬스의 현재 주가는 $5.08 (-0.78%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
씨엔에스파마슈티컬스의 시가총액은 약 $0.01B입니다.
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational